Promising activity of mammalian target of rapamycin inhibitors in hematologic malignancies therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F11%3A00009171" target="_blank" >RIV/00023736:_____/11:00009171 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.2174/157436211794109460" target="_blank" >http://dx.doi.org/10.2174/157436211794109460</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/157436211794109460" target="_blank" >10.2174/157436211794109460</a>

Result language
angličtina
Original language name
Promising activity of mammalian target of rapamycin inhibitors in hematologic malignancies therapy
Original language description
The mammalian target of rapamycin (mTOR) is a downstream mediator of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway which regulates cell survival and proliferation. mTOR is a highly conserved serine/treonine kinase involved in the control of cell growth, protein synthesis, and cell cycle progression. Inhibitor of mTOR pathway have antiproliferative properties in hematological malignancies and are studied in therapeutic trials
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/LC06044" target="_blank" >LC06044: Center for Experimental Hematology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)